Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer

Experimental Physiology

Volumn 98, Issue 9, 2013, Pages 1401-1410

  Gilbert, Stephen E ^a   Tew, Garry A ^a   Bourke, Liam ^b   Winter, Edward M ^a   Rosario, Derek J ^c  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY FAT; BODY MASS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DILATATION; ENDOTHELIAL DYSFUNCTION; FLOW MEDIATED DILATATION; HUMAN; INTRAABDOMINAL FAT; MALE; MEAN ARTERIAL PRESSURE; PHYSICAL ACTIVITY; PROSTATE CANCER; PULSE PRESSURE; RESTING HEART RATE; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE;

EID: 84882583520     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2013.073353     Document Type: Article

References (48)

1. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M & Ouchi Y (2007). Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res 30, 1029-1034.
2. Al Suwaidi J, Higano ST, Holmes DR, Lennon R & Lerman A (2001). Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 37, 1523-1528.
3. American Heart Association (2013). Older Americans and cardiovascular diseases. Statistical fact sheet 2013 update. http://www.heart.org/idc/groups/heart-public/@wcm/@sop/@smd/documents/downloadable/ucm_319574.pdf. [Accessed March 2013.
4. Atkinson G, Batterham AM, Thijssen DH & Green DJ (2013). A new approach to improve the specificity of flow-mediated dilation for indicating endothelial function in cardiovascular research. J Hypertens 31, 287-291.
5. Basaria S, Muller DC, Carducci MA, Egan J & Dobs AS (2006). Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106, 581-588.
6. Black MA, Cable NT, Thijssen DH & Green DJ (2008). Importance of measuring the time course of flow-mediated dilatation in humans. Hypertension 51, 203-210.
7. Bourke L, Chico TJ, Albertsen PC, Hamdy FC & Rosario DJ (2012). Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved. Heart 98, 345-348.
8. Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ & Rosario DJ (2013). Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness Br J Cancer 108, 9-13.
9. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS & Basaria S (2006). Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 18, 494-498.
10. Celermajer DS (1997). Endothelial dysfunction: does it matter? Is it reversible J Am Coll Cardiol 30, 325-333.
11. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK & Deanfield JE (1992). Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340, 1111-1115.
12. Cohen J (1992). A power primer. Psychol Bull 112, 155-159.
13. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A & Kantoff PW (2007). Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25, 2420-2425.
14. Deanfield JE, Halcox JP & Rabelink TJ (2007). Endothelial function and dysfunction: testing and clinical relevance. Circulation 115, 1285-1295.
15. Derweesh IH, DiBlasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, Kitabchi AE & Wake RW (2007). Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 100, 1060-1065.
16. Godin G & Shephard RJ (1985). A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 10, 141-146.
17. Gomella LG (2009). Effective testosterone suppression for prostate cancer: is there a best castration therapy Rev Urol 11, 52-60.
18. Green DJ, Walsh JH, Maiorana A, Best MJ, Taylor RR & O'Driscoll JG (2003). Exercise-induced improvement in endothelial dysfunction is not mediated by changes in CV risk factors: pooled analysis of diverse patient populations. Am J Physiol Heart Circ Physiol 285, H2679-H2687.
19. Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM & Cantwell MM (2010). The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv 4, 128-139.
20. Herman SM, Robinson JT, McCredie RJ, Adams MR, Boyer MJ & Celermajer DS (1997). Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thromb Vasc Biol 17, 2004-2009.
21. Inaba Y, Chen JA & Bergmann SR (2010). Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 26, 631-640.
22. International Agency for Research on Cancer (2012). GLOBOCAN 2008 Cancer fact sheet. Prostate cancer incidence, mortality and prevalence worldwide in 2008 summary. http://www.iarc.fr/. [Accessed March 2013.
23. Jones TH & Saad F (2009). The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 207, 318-327.
24. Keating NL, O'Malley AJ, Freedland SJ & Smith MR (2010). Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102, 39-46.
25. Keating NL, O'Malley AJ, Freedland SJ & Smith MR (2013). Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer Eur Urol 64, 159-166.
26. Kim JA, Montagnani M, Koh KK & Quon MJ (2006). Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113, 1888-1904.
27. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N & American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention tACS, and the American Urological Association (2010). Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 60, 194-201.
28. Lu YL, Kuang L, Zhu H, Wu H, Wang XF, Pang YP, Wang NJ & Yu DL (2007). Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5α-reductase inhibitor. Asian J Androl 9, 843-847.
29. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH & Channer KS (2010). Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96, 1821-1825.
30. Martín-Merino E, Johansson S, Morris T & García Rodríguez LA (2011). Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care. Drug Saf 34, 1061-1077.
31. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP & Carroll PR (2002). Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60, 7-11; discussion 11-12.
32. Milardi D, Grande G, Giampietro A, Vendittelli F, Palumbo S, Tartaglione L, Marana R, Pontecorvi A, de Marinis L, Zuppi C & Capoluongo E (2012). Circulating endothelial cells as marker of endothelial damage in male hypogonadism. J Androl 33, 1291-1297.
33. Mohamedali HZ, Breunis H, Timilshina N & Alibhai SM (2011). Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Can Urol Assoc J 5, 28-32.
34. Molinari C, Battaglia A, Grossini E, Mary DASG, Vassanelli C & Vacca G (2002). The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol 543, 365-372.
35. Parker BA, Trehearn TL & Meendering JR (2009). Pick your Poiseuille: normalizing the shear stimulus in studies of flow-mediated dilation. J Appl Physiol 107, 1357-1359.
36. Perrault LP, Mahlberg F, Breugnot C, Bidouard JP, Villeneuve N, Vilaine JP & Vanhoutte PM (2000). Hypercholesterolemia increases coronary endothelial dysfunction, lipid content, and accelerated atherosclerosis after heart transplantation. Arterioscler Thromb Vasc Biol 20, 728-736.
37. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M & Chierchia SL (1999). Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99, 1666-1670.
38. Schröder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L & Collette L (2009). Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 55, 14-22.
39. Senn S (1994). Testing for baseline balance in clinical trials. Stat Med 13, 1715-1726.
40. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA & Kantoff PW (2002). Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87, 599-603.
41. Smith MR, Lee H & Nathan DM (2006). Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91, 1305-1308.
42. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME & Green DJ (2011). Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 300, H2-H12.
43. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P & Adolfsson J (2010). Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28, 3448-3456.
44. van Londen GJ, Levy ME, Perera S, Nelson JB & Greenspan SL (2008). Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol 68, 172-177.
45. Vita JA & Keaney JF (2002). Endothelial function: a barometer for cardiovascular risk Circulation 106, 640-642.
46. Webb CM, McNeill JG, Hayward CS, de Zeigler D & Collins P (1999). Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100, 1690-1696.
47. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, Lima JA, Crouse JR & Herrington DM (2009). Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 120, 502-509.
48. Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Stenvinkel P, Yaman H, Eyileten T, Caglar K, Oguz Y, Taslipinar A, Vural A, Gok M, Unal HU, Yenicesu M & Carrero JJ (2011). Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol 6, 1617-1625.